<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ANG</journal-id>
<journal-id journal-id-type="hwp">spang</journal-id>
<journal-id journal-id-type="nlm-ta">Angiology</journal-id>
<journal-title>Angiology</journal-title>
<issn pub-type="ppub">0003-3197</issn>
<issn pub-type="epub">1940-1574</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0003319711409565</article-id>
<article-id pub-id-type="publisher-id">10.1177_0003319711409565</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Coronary Heart Disease</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Glomerular Filtration Rate Estimated by the CKD-EPI Formula is a Powerful Predictor of In-Hospital Adverse Clinical Outcomes After an Acute Coronary Syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>AlFaleh</surname>
<given-names>Hussam F.</given-names>
</name>
<degrees>MBBS, FRCPC</degrees>
<xref ref-type="aff" rid="aff1-0003319711409565">1</xref>
<xref ref-type="corresp" rid="corresp1-0003319711409565"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alsuwaida</surname>
<given-names>Abdulkareem O.</given-names>
</name>
<degrees>MBBS, FRCPC</degrees>
<xref ref-type="aff" rid="aff2-0003319711409565">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ullah</surname>
<given-names>Anhar</given-names>
</name>
<degrees>M.Sc</degrees>
<xref ref-type="aff" rid="aff3-0003319711409565">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hersi</surname>
<given-names>Ahmad</given-names>
</name>
<degrees>MBBS, FRCPC</degrees>
<xref ref-type="aff" rid="aff1-0003319711409565">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>AlHabib</surname>
<given-names>Khalid F.</given-names>
</name>
<degrees>MBBS, FRCPC</degrees>
<xref ref-type="aff" rid="aff1-0003319711409565">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>AlShahrani</surname>
<given-names>Ali</given-names>
</name>
<degrees>MBBS</degrees>
<xref ref-type="aff" rid="aff1-0003319711409565">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>AlNemer</surname>
<given-names>Khalid</given-names>
</name>
<degrees>MBBS, FRCPC</degrees>
<xref ref-type="aff" rid="aff3-0003319711409565">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>AlSaif</surname>
<given-names>Shukri</given-names>
</name>
<degrees>MBBS, FRCPC</degrees>
<xref ref-type="aff" rid="aff4-0003319711409565">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Taraben</surname>
<given-names>Amir</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff5-0003319711409565">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ahmed</surname>
<given-names>Waqar H.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff6-0003319711409565">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Balghith</surname>
<given-names>Mohammed A.</given-names>
</name>
<degrees>MBBS, FRCPC</degrees>
<xref ref-type="aff" rid="aff7-0003319711409565">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kashour</surname>
<given-names>Tarek</given-names>
</name>
<degrees>MBBS, FRCPC</degrees>
<xref ref-type="aff" rid="aff8-0003319711409565">8</xref>
</contrib>
</contrib-group>
<aff id="aff1-0003319711409565"><label>1</label>Department of Cardiac Sciences, College of Medicine, King Khalid University Hospital, Riyadh, Saudi Arabia</aff>
<aff id="aff2-0003319711409565"><label>2</label>Department of Medicine, College of Medicine, King Khalid University Hospital, Riyadh, Saudi Arabia</aff>
<aff id="aff3-0003319711409565"><label>3</label>Department of Medicine, Security Forces Hospital, Riyadh, Saudi Arabia</aff>
<aff id="aff4-0003319711409565"><label>4</label>Saud AlBabtain Cardiac Center, Dammam, Saudi Arabia</aff>
<aff id="aff5-0003319711409565"><label>5</label>King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia</aff>
<aff id="aff6-0003319711409565"><label>6</label>King Fahd Armed Forces Hospital, Jeddah, Saudi Arabia</aff>
<aff id="aff7-0003319711409565"><label>7</label>King Abdulaziz Medical City, Cardiac Center, National Guard, Riyadh, Saudi Arabia</aff>
<aff id="aff8-0003319711409565"><label>8</label>Prince Salman Heart Center, King Fahd Medical City, Riyadh, Saudi Arabia</aff>
<author-notes>
<corresp id="corresp1-0003319711409565">Hussam F. AlFaleh, Department of Cardiac Sciences, College of Medicine, King Khalid University Hospital, King Saud University, PO Box 7805, Riyadh 11472, Saudi Arabia Email: <email>halfaleh@hotmail.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>2</month>
<year>2012</year>
</pub-date>
<volume>63</volume>
<issue>2</issue>
<fpage>119</fpage>
<lpage>126</lpage>
<permissions>
<copyright-statement>© SAGE Publications 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>The prognostic value of admission estimated glomerular filtration rate (eGFR) calculated by the new Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula for cardiovascular adverse outcomes in acute coronary syndrome (ACS) was explored. Baseline eGFR was classified as no renal dysfunction (&gt;90 mL/min per 1.73 m<sup>2</sup>), borderline (90-60.1 mL/min per 1.73 m<sup>2</sup>), moderate (60-30.1 mL/min per 1.73 m<sup>2</sup>), or severe (≤30 mL/min per 1.73 m<sup>2</sup>) renal dysfunction. Of the 5034 patients, 3415 (67.8%) had eGFR &lt;90. Compared to patients with an eGFR ≥60 mL/min per 1.73 m<sup>2</sup>, patients with &lt;60 mL/min per 1.73 m<sup>2</sup> were less likely to be treated with β-blockers, angiotensin-converting enzyme inhibitors, or statins, or to undergo percutaneous coronary interventions. Lower eGFR showed a stepwise association with significantly worse adverse in-hospital outcomes. The adjusted odds ratio of in-hospital death with an eGFR &lt;30 mL/min per 1.73 m<sup>2</sup> was 3.1 (95% confidence interval 1.1-8.4, <italic>P</italic> = .0324), compared with an eGFR &gt;90 mL/min per 1.73 m<sup>2</sup>. Estimated glomerular filtration rate calculated by the new CKD-EPI is an independent predictor of major adverse cardiac outcomes in patients with ACS.</p>
</abstract>
<kwd-group>
<kwd>acute coronary syndrome</kwd>
<kwd>renal impairment</kwd>
<kwd>chronic kidney disease</kwd>
<kwd>cardiovascular outcomes</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0003319711409565">
<title>Introduction</title>
<p>The association between cardiovascular disease and renal dysfunction has been extensively explored.<sup><xref ref-type="bibr" rid="bibr1-0003319711409565">1</xref>,<xref ref-type="bibr" rid="bibr2-0003319711409565">2</xref></sup> Numerous studies have documented that renal insufficiency is an independent predictor for both short- and long-term cardiovascular morbidity and mortality.<sup><xref ref-type="bibr" rid="bibr3-0003319711409565">3</xref><xref ref-type="bibr" rid="bibr4-0003319711409565"/><xref ref-type="bibr" rid="bibr5-0003319711409565"/><xref ref-type="bibr" rid="bibr6-0003319711409565"/><xref ref-type="bibr" rid="bibr7-0003319711409565"/><xref ref-type="bibr" rid="bibr8-0003319711409565"/><xref ref-type="bibr" rid="bibr9-0003319711409565"/>–<xref ref-type="bibr" rid="bibr10-0003319711409565">10</xref></sup> Moderate renal dysfunction at baseline in a broad range of patients with acute coronary syndrome (ACS) is associated with at least a 2-fold increase in mortality.<sup><xref ref-type="bibr" rid="bibr4-0003319711409565">4</xref><xref ref-type="bibr" rid="bibr5-0003319711409565"/>–<xref ref-type="bibr" rid="bibr6-0003319711409565">6</xref></sup> The prognostic impact of estimated glomerular filtration rate (eGFR) calculated by the newly validated Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula in a broad spectrum of patients with ACS has not been studied.<sup><xref ref-type="bibr" rid="bibr11-0003319711409565">11</xref></sup> Accordingly, our main objective was to determine whether baseline eGFR calculated using this formula in patients with ACS is an independent predictor of in-hospital adverse cardiovascular events. In addition, we compared eGFR calculated by the CKD-EPI formula with that calculated by the Modification of Diet in Renal Disease (MDRD) formula, with regard to classification of renal function and prognostic value in an ACS cohort.</p>
</sec>
<sec id="section2-0003319711409565">
<title>Methods</title>
<p>The Saudi Project for Assessment of Coronary Events (SPACE) study is a prospective, multicenter, observational study involving all consecutive patients with ACS admitted to the participating hospitals. It consisted of 2 phases covering from December 2005 until December 2007. The full description of the phase I design has been described.<sup><xref ref-type="bibr" rid="bibr12-0003319711409565">12</xref></sup> SPACE phase II, which included more hospitals, was conducted from December 2006 until the end of December 2007. A total of 17 hospitals across Saudi Arabia participated in this registry. Where required, ethics approval was obtained from the institutional review board of individual hospitals. Patients with ACS included those with ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), and unstable angina. The diagnosis of the different types of ACS, as well as of all other adverse end points analyzed in this study, was based on the 2001 definitions of the Joint Committee of the European Society of Cardiology/American College of Cardiology.<sup><xref ref-type="bibr" rid="bibr13-0003319711409565">13</xref></sup>
</p>
<p>Data collection was performed using a standardized paper case report form in phase I and an Internet electronic case report form in phase II. Collected data included patient demographics, past medical history, provisional diagnosis on admission and final discharge diagnosis, electrocardiogram (ECG) findings, laboratory investigations, medical therapy, use of cardiac procedures and interventions, in-hospital outcomes, and overall mortality.</p>
<sec id="section3-0003319711409565">
<title>Study Patients</title>
<p>For inclusion in this analysis, patients with ACS enrolled in SPACE phases I and II had to have an admission serum creatinine level. Serum creatinine measurement was performed locally at each participating hospital and obtained within 24 hours of hospital admission.</p>
<p>We stratified kidney function by eGFR using the CKD-EPI formula.<sup><xref ref-type="bibr" rid="bibr11-0003319711409565">11</xref></sup> This formula was used instead of the abbreviated MDRD formula because the former has been shown to be more accurate and to carry less bias, especially at higher eGFR levels.<sup><xref ref-type="bibr" rid="bibr14-0003319711409565">14</xref></sup>
</p>
<p>Patients were classified according to their eGFR level at baseline into 4 groups: group 1 (&gt;90.1 mL/min per 1.73 m<sup>2</sup>); group 2 (90-60.1 mL/min per 1.73 m<sup>2</sup>); group 3 (60-30. 1 mL/min per 1.73 m<sup>2</sup>); and group 4 (≤30 mL/min per 1.73 m<sup>2</sup>).</p>
<p>Baseline characteristics, clinical presentations, and in-hospital therapies were compared across the different eGFR groups. The study outcomes included in-hospital all-cause mortality, re-infarction, heart failure, cardiogenic shock, stroke, and major bleeding. In addition, we compared the eGFR calculated using the CKD-EPI formula versus values obtained using 4 variables of MDRD formula in predicting in-hospital mortality.</p>
</sec>
<sec id="section4-0003319711409565">
<title>Statistical Analysis</title>
<p>Categorical data were summarized with absolute numbers and percentages. Numeric data were summarized with means and standard deviations (SDs). Comparisons among different groups were performed using the χ<sup>2</sup> test for categorical variables and analysis of variance or Kruskal-Wallis test for continuous variables. Multiple logistic regression was used to estimate the adjusted odds ratios. Adjustments were made for age, body mass index (BMI), gender, smoking, dyslipidemia, diabetes, history of hypertension, heart rate, systolic blood pressure, past coronary artery disease, peripheral artery disease, diagnostic coronary angiography, percutaneous coronary interventions (PCIs), coronary artery bypass graft (CABG), and all pharmacological therapies. Bland-Altman analysis was performed to evaluate the difference between eGFR calculated by the CKD-EPI and MDRD formulas. To study the agreement between eGFR categories as identified by CKD-EPI and MDRD, the kappa statistic was used along with 95% confidence intervals (95% CIs). To compare the prevalence of normal eGFR as calculated using the CKD-EPI formula and MDRD formula, we used McNemar test, while the actual eGFR level calculated by the 2 formulas were compared using Wilcoxon signed-rank test. To compare the predictive power of the logistic regression model for predicting the mortality using eGFR categories, we used the area under the receiver operating characteristic (ROC) curve, and the 2 ROC curves were compared using ROC SAS macro. All analyses were performed using SAS/STAT software (SAS Institute Inc, Cary, North Carolina).</p>
</sec>
</sec>
<sec id="section5-0003319711409565">
<title>Results</title>
<p>A total of 5034 patients with ACS with the baseline creatinine levels available at the time of admission were included in the study. The mean creatinine level was 107 ± 79 μmol/L, and the mean eGFR was 74 ± 25 mL/min per 1.73 m<sup>2</sup>. <xref ref-type="fig" rid="fig1-0003319711409565">Figure 1</xref>
 shows the distribution of eGFR values in the study cohort. A total of 3415 (67.8%) patients had an eGFR &lt;90 mL/min per 1.73 m<sup>2</sup>. <xref ref-type="table" rid="table1-0003319711409565">Table 1</xref>
 depicts the baseline characteristics and the number of patients in each eGFR group. Patients were significantly older and more likely to be female and Saudi nationals and were more likely to have risk factors for atherosclerosis with lower eGFR in a stepwise fashion. In addition, a previous history of vascular disease was significantly more prevalent among patients with moderate and severe kidney dysfunction. Those with moderate and severe renal dysfunction also had a significantly higher BMI.</p>
<fig id="fig1-0003319711409565" position="float">
<label>Figure 1.</label>
<caption>
<p>Distribution of eGFR for patients with ACS. ACS indicates acute coronary syndrome; eGFR, estimated glomerular filtration rate.</p>
</caption>
<graphic xlink:href="10.1177_0003319711409565-fig1.tif"/>
</fig>
<table-wrap id="table1-0003319711409565" position="float">
<label>Table 1.</label>
<caption>
<p>Baseline Characteristics</p>
</caption>
<graphic alternate-form-of="table1-0003319711409565" xlink:href="10.1177_0003319711409565-table1.tif"/>
<table>
<thead>
<tr>
<th rowspan="2">
</th>
<th colspan="4">Estimated Glomerular Filtration Rate (mL/min per 1.73 m<sup>2</sup>)</th>
<th>
</th>
</tr>
<tr>
<th>Group 1 (&gt;90), n = 1619, n (%)</th>
<th>Group 2 (90-60.1), n = 2090, n (%)</th>
<th>Group 3 (60-30.1), n = 1042, n (%)</th>
<th>Group 4 (≤30), n = 283, n (%)</th>
<th>
<italic>P</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>Males</td>
<td>1354 (83.6)</td>
<td>1653 (79)</td>
<td>709 (67.9)</td>
<td>188 (66.2)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Age (mean ± SD)</td>
<td>50.2 ± 10.3</td>
<td>58.9 ± 11.9</td>
<td>66 ± 11.8</td>
<td>65 ± 12.6</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Saudi</td>
<td>1267 (78.4)</td>
<td>1708 (81.7)</td>
<td>921 (88.2)</td>
<td>256 (90.5)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Diabetes</td>
<td>862 (53.3)</td>
<td>1159 (55.5)</td>
<td>690 (66.4)</td>
<td>215 (76.2)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Hypertension</td>
<td>708 (43.8)</td>
<td>1105 (53)</td>
<td>736 (71.3)</td>
<td>233 (82.3)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Dyslipidemia</td>
<td>623 (38.6)</td>
<td>842 (40.4)</td>
<td>472 (45.7)</td>
<td>145 (51.4)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Smoking</td>
<td>759 (46.9)</td>
<td>648 (31)</td>
<td>179 (17.2)</td>
<td>41 (14.5)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Prior PAD</td>
<td>71 (4.4)</td>
<td>134 (6.4)</td>
<td>115 (11.1)</td>
<td>44 (15.6)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Prior CAD</td>
<td>591 (36.5)</td>
<td>851 (40.8)</td>
<td>546 (54.5)</td>
<td>154 (54.6)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Prior CABG</td>
<td>53 (3.2)</td>
<td>123 (5.9)</td>
<td>96 (9.2)</td>
<td>24 (8.5)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Prior CVA</td>
<td>49 (3.0)</td>
<td>111 (5.3)</td>
<td>120 (11.5)</td>
<td>29 (10.2)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>BMI (mean ± SD)</td>
<td>28.2 ± 5.2</td>
<td>28.0 ± 5.1</td>
<td>28.7 ± 5.4</td>
<td>27.8 ± 7.2</td>
<td>.049</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0003319711409565">
<p>Abbreviations: BMI, body mass index; CABG, coronary artery bypass surgery; CAD, coronary artery disease; CVA, cerebrovascular accidents; PAD, peripheral arterial disease; SD, standard deviation.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<sec id="section6-0003319711409565">
<title>Estimated GFR</title>
<p>The mean eGFR calculated by the MDRD formula was 75.6 versus 76.6 mL/min per 1.73 m<sup>2</sup> using the CKD-EPI formula (mean difference 0.09384 and interquartile range of 5.35, <italic>P</italic> = .469). <italic>There was more agreement between the 2 formulas in lower eGFR levels; however, the MDRD formula classified more patients into eGFR &lt; 90 ml/min/1.73m<sup>2</sup> compared with the CKD-EPI formula (kappa value 0.85, 95% CI 0.84-0.86, p &lt; 0.0001).</italic>
<xref ref-type="fig" rid="fig2-0003319711409565">Figure 2</xref>
 shows the Bland-Altman analysis results. The prevalence of normal eGFR as estimated using the CKD-EPI formula was higher than that obtained using the MDRD formula (32%, n = 1620 vs 28%, n = 1412, <italic>P</italic> &lt; .0001).</p>
<fig id="fig2-0003319711409565" position="float">
<label>Figure 2.</label>
<caption>
<p>Bland-Altman plot of the MDRD and CKD-EPI formula in classifying eGFR level. CKD-EPI indicates Chronic Kidney Disease Epidemiology Collaboration formula; eGFR, estimated glomerular filtration rate; MDRD, modification of diet in renal disease formula.</p>
</caption>
<graphic xlink:href="10.1177_0003319711409565-fig2.tif"/>
</fig>
</sec>
<sec id="section7-0003319711409565">
<title>Clinical Presentation</title>
<p>
<xref ref-type="table" rid="table2-0003319711409565">Table 2</xref>
 shows the clinical presentations of the study cohort. Patients with lower eGFR were more likely to present with tachycardia and hypotension. Moreover, they were more likely to present with heart failure and low ejection fraction (&lt;35%) and to have a high-risk coronary anatomy defined as either severe 3-vessel or left main stem coronary artery disease.</p>
<table-wrap id="table2-0003319711409565" position="float">
<label>Table 2.</label>
<caption>
<p>Clinical Presentation</p>
</caption>
<graphic alternate-form-of="table2-0003319711409565" xlink:href="10.1177_0003319711409565-table2.tif"/>
<table>
<thead>
<tr>
<th rowspan="1">
</th>
<th colspan="4">Estimated Glomerular Filtration Rate (mL/min per 1.73 m<sup>2</sup>)</th>
<th>
</th>
</tr>
<tr>
<th>
</th>
<th>Group 1 (&gt;90), n = 1619, n (%)</th>
<th>Group 2 (90-60.1), n = 2090, n (%)</th>
<th>Group 3 (60-30.1), n = 1042, n (%)</th>
<th>Group 4 (≤30), n = 283, n (%)</th>
<th>
<italic>P</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>HR &gt;100 bpm (mean, SD)</td>
<td>171 (11.74)</td>
<td>258 (13.67)</td>
<td>198 (20.82)</td>
<td>50 (19.23)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>SBP &lt;90 mm Hg (mean, SD)</td>
<td>24 (1.65)</td>
<td>54 (2.86)</td>
<td>58 (6.11)</td>
<td>12 (4.63)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Heart failure</td>
<td>177 (12.19)</td>
<td>343 (18.27)</td>
<td>321 (33.72)</td>
<td>98 (37.40)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>STEMI</td>
<td>727 (44.88)</td>
<td>910 (43.48)</td>
<td>377 (36.11)</td>
<td>73 (25.70)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>NSTEMI</td>
<td>496 (30.62)</td>
<td>714 (34.11)</td>
<td>459 (44.0)</td>
<td>169 (59.50)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Unstable angina</td>
<td>397 (24.51)</td>
<td>469 (22.41)</td>
<td>207 (19.83)</td>
<td>42 (14.78)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>LVEF % (&lt;35%)</td>
<td>438 (29.28)</td>
<td>720 (36.40)</td>
<td>436 (41.76)</td>
<td>123 (40.32)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>3VD/LM disease</td>
<td>350 (29.76)</td>
<td>520 (34.69)</td>
<td>297 (47.98)</td>
<td>56 (53.33)</td>
<td>&lt;.001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0003319711409565">
<p>Abbreviations: bpm, beats per minute; HR, heart rate; SBP, systolic blood pressure; STEMI, ST-elevation myocardial infarction; NSTEMI, non-ST-elevation myocardial infarction; LVEF, left ventricular ejection fraction; 3VD/LM, 3-vessel disease/left main stem coronary disease.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>With regard to the type of ACS presentation, NSTEMI was seen significantly more in patients with lowest kidney function categories. On the other hand, patients with an eGFR &gt; 60 mL/min per 1.73 m<sup>2</sup> were significantly more likely to present with STEMI or unstable angina.</p>
</sec>
<sec id="section8-0003319711409565">
<title>Hospital Treatment</title>
<p>With some exceptions, therapies were equally given across all eGFR categories. β-Blockers, angiotensin-converting enzyme inhibitors (ACEIs), statins, and glycoprotein IIb/IIIa inhibitors were used significantly less frequently with decreasing eGFR. On the other hand, angiotensin receptor blockers were used significantly more with decreasing eGFR. Patients presenting with STEMI were less likely to receive thrombolytic therapy if they had eGFR &gt; 60 mL/min per 1.73 m<sup>2</sup> (<xref ref-type="table" rid="table3-0003319711409565">Table 3</xref>
).</p>
<table-wrap id="table3-0003319711409565" position="float">
<label>Table 3.</label>
<caption>
<p>In-Hospital Therapies</p>
</caption>
<graphic alternate-form-of="table3-0003319711409565" xlink:href="10.1177_0003319711409565-table3.tif"/>
<table>
<thead>
<tr>
<th rowspan="1">
</th>
<th colspan="4">Estimated Glomerular Filtration Rate (mL/min per 1.73 m<sup>2</sup>)</th>
<th>
</th>
</tr>
<tr>
<th>
</th>
<th>Group 1 (&gt;90), n = 1619, n (%)</th>
<th>Group 2 (90-60.1), n = 2090, n (%)</th>
<th>Group 3 (60-30.1), n = 1042, n (%)</th>
<th>Group 4 (≤30), n = 283, n (%)</th>
<th>
<italic>P</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aspirin</td>
<td>1593 (98.5)</td>
<td>2040 (97.6)</td>
<td>1009 (97.3)</td>
<td>273 (96.5)</td>
<td>.07</td>
</tr>
<tr>
<td>Clopidogrel</td>
<td>1349 (83.4)</td>
<td>1771 (84.8)</td>
<td>876 (84.5)</td>
<td>227 (80.2)</td>
<td>.20</td>
</tr>
<tr>
<td>β-Blockers</td>
<td>1384 (85.5)</td>
<td>1708 (81.7)</td>
<td>800 (77.3)</td>
<td>211 (74.6)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Statins</td>
<td>1531 (94.6)</td>
<td>1946 (93.1)</td>
<td>961 (92.7)</td>
<td>254 (89.8)</td>
<td>.01</td>
</tr>
<tr>
<td>ACEIs</td>
<td>1135 (70.2)</td>
<td>1486 (71.1)</td>
<td>731 (70.5)</td>
<td>143 (50.7)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>ARBs</td>
<td>70 (4.3)</td>
<td>107 (5.1)</td>
<td>90 (8.7)</td>
<td>29 (10.3)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Heparin</td>
<td>1324 (81.8)</td>
<td>1730 (82.9)</td>
<td>894 (85.8)</td>
<td>220 (77.7)</td>
<td>.005</td>
</tr>
<tr>
<td>GP IIb/IIIa</td>
<td>491 (30.3)</td>
<td>608 (29.1)</td>
<td>251 (24.1)</td>
<td>37 (13.1)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Thrombolytic use</td>
<td>432 (65.1)</td>
<td>508 (61.5)</td>
<td>168 (50)</td>
<td>34 (54)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Diagnostic coronary angiography</td>
<td>1174 (72.5)</td>
<td>1499 (71.6)</td>
<td>620 (59.4)</td>
<td>103 (36.3)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>PCI</td>
<td>672 (41.7)</td>
<td>773 (37.1)</td>
<td>281 (27)</td>
<td>49 (17.3)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>PCI within 7 days of admission</td>
<td>437 (95.2)</td>
<td>519 (95.1)</td>
<td>178 (91.3)</td>
<td>22 (73.3)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>CABG</td>
<td>149 (9.3)</td>
<td>180 (8.7)</td>
<td>80 (7.7)</td>
<td>15 (5.3)</td>
<td>.29</td>
</tr>
<tr>
<td>Median length of hospital stay (IQR)</td>
<td>4 (4)</td>
<td>5 (5)</td>
<td>6 (7)</td>
<td>6 (9)</td>
<td>&lt;.001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0003319711409565">
<p>Abbreviations: ACEIs, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; CABG, coronary artery bypass surgery; GP, glycoprotein; IQR, interquartile range; PCI, percutaneous coronary intervention.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>As would be expected, the use of diagnostic coronary angiography and PCI was generally less with lower eGFR. In addition, when looking at the rate of PCI performance within 7 days of hospital admission, there was a significant delay with decreasing renal function (<xref ref-type="table" rid="table3-0003319711409565">Table 3</xref>).</p>
</sec>
<sec id="section9-0003319711409565">
<title>In-hospital Outcomes</title>
<p>
<xref ref-type="fig" rid="fig3-0003319711409565">Figure 3</xref>
 shows in-hospital outcomes stratified by eGFR level. Decreasing eGFR was associated with a significantly higher all-cause mortality, re-infarction, heart failure, cardiogenic shock, major bleeding, and cerebrovascular accident (CVA). With the eGFR &gt;90 mL/min per 1.73 m<sup>2</sup> group as the reference, patients with lower eGFR had a significantly higher crude mortality, re-infarction, heart failure, cardiogenic shock, major bleeding, and CVA. Multivariate analysis adjusting for important confounders confirmed that eGFR remained as an independent predictor of all adverse in-hospital outcomes, except for stroke/transient ischemic attack, and major bleeding, which was predictive only in patients with an eGFR &lt; 30 mL/min per 1.73 m<sup>2</sup> (<xref ref-type="table" rid="table4-0003319711409565">Table 4</xref>
).</p>
<fig id="fig3-0003319711409565" position="float">
<label>Figure 3.</label>
<caption>
<p>Rate of in-hospital adverse cardiac outcomes. CHF indicates congestive heart failure; Re-MI, recurrent myocardial infarction; TIA, transient ischemic attack.</p>
</caption>
<graphic xlink:href="10.1177_0003319711409565-fig3.tif"/>
</fig>
<table-wrap id="table4-0003319711409565" position="float">
<label>Table 4.</label>
<caption>
<p>Crude and Adjusted Odds Ratios (ORs) for In-hospital Outcomes<sup><xref ref-type="table-fn" rid="table-fn5-0003319711409565">a</xref></sup>
</p>
</caption>
<graphic alternate-form-of="table4-0003319711409565" xlink:href="10.1177_0003319711409565-table4.tif"/>
<table>
<thead>
<tr>
<th>Outcomes</th>
<th>eGFR (mL/min per 1.73 m<sup>2</sup>)</th>
<th>Unadjusted OR (95% CI)</th>
<th>
<italic>P</italic> Value</th>
<th>Adjusted OR (95% CI)</th>
<th>
<italic>P</italic> Value</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="3">Death</td>
<td>≤30</td>
<td>14.1 (7.5-6.3)</td>
<td>&lt;.001</td>
<td>3.1 (1.1-8.4)</td>
<td>.0324</td>
</tr>
<tr>
<td>30.1-60</td>
<td>7.9 (4.5-13.9)</td>
<td>&lt;.001</td>
<td>2.5 (1.1-5.6)</td>
<td>.0304</td>
</tr>
<tr>
<td>60-90</td>
<td>1.8 (1.0-3.2)</td>
<td>.0672</td>
<td>1.02 (0.5-2.28)</td>
<td>.946</td>
</tr>
<tr>
<td rowspan="3">Re-MI</td>
<td>≤30</td>
<td>7.9 (3.3-18.9)</td>
<td>&lt;.001</td>
<td>11.6 (2.1-65.5)</td>
<td>.0053</td>
</tr>
<tr>
<td>30.1-60</td>
<td>3.4 (1.8-8.4)</td>
<td>&lt;.001</td>
<td>9.7 (2.5-38.4)</td>
<td>.0012</td>
</tr>
<tr>
<td>60-90</td>
<td>2.9 (1.4-6.0)</td>
<td>&lt;.001</td>
<td>4.27 (1.2-15.4)</td>
<td>.026</td>
</tr>
<tr>
<td rowspan="3">Major bleeding</td>
<td>≤30</td>
<td>9.7 (4.0-23.5)</td>
<td>&lt;.001</td>
<td>10.0 (2.7-36.5)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>30.1-60</td>
<td>4.5 (2.0-10.2)</td>
<td>&lt;.001</td>
<td>2.81 (0.8-9.5)</td>
<td>.094</td>
</tr>
<tr>
<td>60-90</td>
<td>2.3 (1.0-5.2)</td>
<td>&lt;.001</td>
<td>1.90 (0.6-5.6)</td>
<td>.242</td>
</tr>
<tr>
<td rowspan="3">Stroke/TIA</td>
<td>≤30</td>
<td>2.3 (0.73-7.3)</td>
<td>.162</td>
<td>2.4 (0.5-11.5)</td>
<td>.273</td>
</tr>
<tr>
<td>30.1-60</td>
<td>3.1 (1.5-6.8)</td>
<td>.003</td>
<td>2.3 (0.7-7.2)</td>
<td>.171</td>
</tr>
<tr>
<td>60-90</td>
<td>1.1 (0.5-2.5)</td>
<td>.843</td>
<td>0.9 (0.3-2.9)</td>
<td>.977</td>
</tr>
<tr>
<td rowspan="3">Congestive heart failure</td>
<td>≤30</td>
<td>6.8 (4.7-9.8)</td>
<td>&lt;.001</td>
<td>3.6 (2.0-6.7)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>30.1-60</td>
<td>5.9 (4.4-7.9)</td>
<td>&lt;.001</td>
<td>2.6 (1.6-4.1)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>60-90</td>
<td>2.0 (1.5-2.7)</td>
<td>&lt;.001</td>
<td>1.4 (1.0-2.3)</td>
<td>.074</td>
</tr>
<tr>
<td rowspan="3">Cardiogenic shock</td>
<td>≤30</td>
<td>8.3 (5.1-13.9)</td>
<td>&lt;.001</td>
<td>4.4 1.9-10.2)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>30.1-60</td>
<td>5.3 (3.5-8.2)</td>
<td>&lt;.001</td>
<td>2.37 (1.2-4.7)</td>
<td>.011</td>
</tr>
<tr>
<td>60-90</td>
<td>1.6 (1.1-2.5)</td>
<td>.028</td>
<td>1.4 (0.8-2.7)</td>
<td>.210</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0003319711409565">
<p>Abbreviations: CI, confidence interval; GFR, glomerular filtration rate; ORs, odds ratios; Re-MI, recurrent myocardial infarction; TIA, transient ischemic attack.</p>
</fn>
<fn id="table-fn5-0003319711409565">
<p>
<sup>a</sup> Reference group is eGFR &gt;90 mL/min per 1.73 m<sup>2</sup>.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The adjusted odds ratios for in-hospital mortality in patients with an eGFR ≤30 and 30.1 to 60 mL/min per 1.73 m<sup>2</sup> using the CKD-EPI formula were 3.1 (95% CI 1.1-8.4, <italic>P</italic> = .03) and 2.5 (95% CI 1.1-5.6, <italic>P</italic> = .03), respectively, while they were 1.9 (95% CI 0.9-3.8, <italic>P</italic> = .08) and 3.20 (95% CI 1.4-7.5, <italic>P</italic> = .007), respectively, when the eGFR was derived using the MDRD formula. With the consideration of eGFR as a predictor of in-hospital mortality, the predictive power of the CKD-EPI formula was significantly better than that of the MDRD formula (area under the curve 0.74 vs 0.71, <italic>P</italic> = .0002).</p>
</sec>
</sec>
<sec id="section10-0003319711409565">
<title>Discussion</title>
<p>Despite the relatively young age of ACS presentation in this registry, a majority of patients (67.9%) had some degree of renal dysfunction that is defined as an eGFR &lt;60 mL/min. As expected, the CKD-EPI formula was less likely to label patients with renal dysfunction. This formula has previously been shown to carry less bias at higher GFR levels, and misclassification of the true GFR level is therefore less when compared with the abbreviated MDRD formula.<sup><xref ref-type="bibr" rid="bibr11-0003319711409565">11</xref>,<xref ref-type="bibr" rid="bibr14-0003319711409565">14</xref></sup> The high prevalence of renal dysfunction in this cohort may be related to a higher prevalence of vascular disease risk factors and vascular comorbidities, all potential precursors of chronic kidney disease.<sup><xref ref-type="bibr" rid="bibr1-0003319711409565">1</xref></sup> We also found that in “real-world” unselected Middle-Eastern patients, in-hospital rates of major adverse cardiac events (MACEs) were significantly higher among patients with moderate or severe renal dysfunction compared to patients with normal or mild renal dysfunction. Moreover, an eGFR measured by the CKD-EPI formula independently predicted in-hospital mortality and was significantly more predictive of this hard end point compared with that estimated using the more traditional MDRD formula. This observation has, to our knowledge, not been demonstrated previously.</p>
<p>Several important management differences/gaps were noted in patients with the worst eGFR categories. Despite the higher risk profile upon presentation in patients with moderate or severe renal dysfunction, namely heart failure, moderate or severe left ventricular (LV) systolic dysfunction, and a higher-risk coronary anatomy, there was a lower rate of PCI. Moreover, there was a significant delay in the performance of PCI following hospital admission. This lower use of PCI could be explained on the basis of extensive/diffuse coronary artery disease, which is more appropriate for CABG or medical therapy; the delay in PCI performance thus is possibly related to the efforts to mitigate the risk of contrast-induced nephropathy with measures such as intravenous hydration. Previous similar registries have demonstrated the medical therapy gaps seen with lower eGFR categories in this study.<sup><xref ref-type="bibr" rid="bibr4-0003319711409565">4</xref>,<xref ref-type="bibr" rid="bibr8-0003319711409565">8</xref>,<xref ref-type="bibr" rid="bibr15-0003319711409565">15</xref></sup> Some of these gaps may be “appropriate” and could be justified by certain relative or absolute contraindications seen more commonly in our study cohort with renal dysfunction, such as hypotension (in the case of β-blockers and ACEIs), risk of nephrotoxicity (ACEIs), acute heart failure (β-blockers), lower renal clearance, higher risk of bleeding (glycoprotein IIb/IIIa inhibitors), or possibly delayed/atypical clinical presentation in STEMI patients (thrombolytic therapy). Statin therapy was used less in patients with renal dysfunction. The reluctance to use these agents may stem from physicians’ fear of inducing rhabdomyolysis in these patients. Statins have been shown to be safe in these patients and to reduce cardiovascular events in addition to a potential reno-protective role.<sup><xref ref-type="bibr" rid="bibr16-0003319711409565">16</xref></sup> Therefore, it is conceivable that the adverse prognosis seen in the groups with advanced renal dysfunction could have been attenuated when statins were used more frequently.</p>
<p>Hospital stay was significantly longer in patients with severe renal dysfunction compared to those with normal or mild renal dysfunction, an observation seen in other studies. In addition, the absolute mean length of stay was longer compared with other registries (10.6 ± 28.8 in this study vs 6.6 ± 6 in the Gulf Registry of Acute Coronary Events, or Gulf RACE, and 8.8 ± 7.3 in the SYndromes COronaires aigus et MOdalités de leur prise en charge selon la fonction REnale or SYCOMORE registry).<sup><xref ref-type="bibr" rid="bibr8-0003319711409565">8</xref></sup> The higher MACE with lower eGFR values seen in our study confirms findings from previous studies.<sup><xref ref-type="bibr" rid="bibr3-0003319711409565">3</xref><xref ref-type="bibr" rid="bibr4-0003319711409565"/>–<xref ref-type="bibr" rid="bibr5-0003319711409565">5</xref>,<xref ref-type="bibr" rid="bibr7-0003319711409565">7</xref>,<xref ref-type="bibr" rid="bibr8-0003319711409565">8</xref>,<xref ref-type="bibr" rid="bibr10-0003319711409565">10</xref>,<xref ref-type="bibr" rid="bibr15-0003319711409565">15</xref>,<xref ref-type="bibr" rid="bibr17-0003319711409565">17</xref></sup> Patients with an eGFR &lt; 30 mL/min per 1.73 m<sup>2</sup> had a mortality rate of 11.6% and were almost 4 times more likely to die compared with other patient groups, after adjustment for all potential confounders. This mortality rate is comparable with that of the Global Registry of Acute Coronary Events (GRACE) and of another Middle-Eastern registry, the Gulf RACE Registry (12.2% and 13%, respectively), but less than the Greek Study of Acute Coronary Events ([GREEK]; 16%).<sup><xref ref-type="bibr" rid="bibr4-0003319711409565">4</xref>,<xref ref-type="bibr" rid="bibr5-0003319711409565">5</xref>,<xref ref-type="bibr" rid="bibr15-0003319711409565">15</xref></sup> Higher MACE rates could be attributed to the higher risk profile upon presentation, including moderate to severe left-ventricular systolic dysfunction and a higher risk coronary anatomy.</p>
<p>Major bleeding episodes were several folds higher in patients with severe renal dysfunction compared to other categories of renal dysfunction, or normal renal function, and is higher than what has been reported in previous registries.<sup><xref ref-type="bibr" rid="bibr4-0003319711409565">4</xref>,<xref ref-type="bibr" rid="bibr5-0003319711409565">5</xref>,<xref ref-type="bibr" rid="bibr8-0003319711409565">8</xref></sup> There was a significant trend in the risk of stroke or transient ischemic attacks with worsening renal function; however, the adjusted odds ratio for an eGFR &lt; 30 mL/min per 1.73 m<sup>2</sup> was not significantly high, likely owing to a low number of events due to a smaller sample size in this creatinine clearance group. The higher risk of stroke in our study has been demonstrated in previous reports, however<sup><xref ref-type="bibr" rid="bibr3-0003319711409565">3</xref>,<xref ref-type="bibr" rid="bibr18-0003319711409565">18</xref></sup>; and bleeding risk increases progressively with lower GFR.<sup><xref ref-type="bibr" rid="bibr4-0003319711409565">4</xref>,<xref ref-type="bibr" rid="bibr8-0003319711409565">8</xref></sup> Plausible explanations for excess bleeding include decreased platelet function in patients with chronic kidney disease combined with further platelet function inhibition by antiplatelet agents such as clopidogrel.<sup><xref ref-type="bibr" rid="bibr19-0003319711409565">19</xref></sup> Other factors can include underestimation of the degree of renal dysfunction when assessing only serum creatinine rather than eGFR, which potentially leads to dosing errors with antithrombotic agents and glycoprotein IIb/IIIa inhibitors commonly used in patients with ACS.<sup><xref ref-type="bibr" rid="bibr20-0003319711409565">20</xref></sup>
</p>
<p>Our study has several limitations. It was an observational, nonrandomized study, and inherent biases in this study design therefore could not be avoided but were potentially reduced by the use of multivariate analysis. Estimated glomerular filtration rate was calculated but not measured. Estimated glomerular filtration rate, however, is practical and has been used in various patient populations. Data on the use of renal replacement therapy and long-term outcomes were not prospectively collected in our registry; therefore, these end points were not included as outcome measures in this analysis.</p>
<p>Our findings add to the growing body of evidence of the deleterious effects of baseline renal dysfunction in patients presenting with ACS and provide new insights into the prognostic value of GFR estimated using the CKD-EPI formula. The CKD-EPI-derived eGFR significantly outperformed the MDRD formula in predicting in-hospital mortality in patients with ACS. The majority of our patients had some degree of renal dysfunction on admission, and systematic assessment of eGFR is therefore paramount in risk stratification of patients, tailoring therapy, and early, aggressive management. Future research should focus on prospectively evaluating the effect of aggressive therapy in this high-risk group.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>The SPACE registry is managed under the auspices of the Saudi Heart Association and financially sponsored by Sanofi-Aventis, which had no role in data extraction or analyses, the writing of the manuscript, or the decision to submit the manuscript for publication. The College of Medicine Research Center at King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia, provided ethical approval. We thank Zenaida Ramoso for secretarial assistance.</p>
</ack>
<fn-group>
<fn fn-type="conflict" id="fn1-0003319711409565">
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0003319711409565">
<p> The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article:</p>
<p>Sanofi-Aventis company financially sponsored this registry, and the College of Medicine Research Center at King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia, provided partial funding.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0003319711409565">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wright</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hutchison</surname>
<given-names>A.</given-names>
</name>
</person-group> <article-title>Cardiovascular disease in patients with chronic kidney disease</article-title>. <source>Vasc Health Risk Manag</source>. <year>2009</year>;<volume>5</volume>:<fpage>713</fpage>–<lpage>722</lpage>.</citation>
</ref>
<ref id="bibr2-0003319711409565">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ernesto</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Mark</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>Johannes</surname>
<given-names>FEM.</given-names>
</name>
</person-group> <article-title>Chronic kidney disease: effects on the cardiovascular system</article-title>. <source>Circulation</source>. <year>2007</year>;<volume>116</volume>(<issue>1</issue>):<fpage>85</fpage>–<lpage>97</lpage>.</citation>
</ref>
<ref id="bibr3-0003319711409565">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anavekar</surname>
<given-names>NS</given-names>
</name>
<name>
<surname>McMurray</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Velazquez</surname>
<given-names>EJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction</article-title>. <source>N Engl J Med</source>. <year>2004</year>;<volume>351</volume>(<issue>13</issue>):<fpage>1285</fpage>–<lpage>1295</lpage>.</citation>
</ref>
<ref id="bibr4-0003319711409565">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Santopinto</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Fox</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Goldberg</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Budaj</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Piñero</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Avezum</surname>
<given-names>A.</given-names>
</name>
</person-group> <article-title>Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: findings from the global registry of acute coronary events (GRACE)</article-title>. <source>Heart</source>. <year>2003</year>;<volume>89</volume>(<issue>9</issue>):<fpage>1003</fpage>–<lpage>1008</lpage>.</citation>
</ref>
<ref id="bibr5-0003319711409565">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pitsavos</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kourlaba</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Panagiotakos</surname>
<given-names>DB</given-names>
</name>
<etal/>
</person-group>. <article-title>Association of creatinine clearance and in-hospital mortality in patients with acute coronary syndromes, the GREECS Study</article-title>. <source>Circ J</source>. <year>2007</year>;<volume>71</volume>(<issue>1</issue>):<fpage>9</fpage>–<lpage>14</lpage>.</citation>
</ref>
<ref id="bibr6-0003319711409565">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Masoudi</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Plomondon</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Magid</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Sales</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rumsfeld</surname>
<given-names>JS.</given-names>
</name>
</person-group> <article-title>Renal insufficiency and mortality from acute coronary syndromes</article-title>. <source>Am Heart J</source>. <year>2004</year>;<volume>147</volume>(<issue>4</issue>):<fpage>623</fpage>–<lpage>629</lpage>.</citation>
</ref>
<ref id="bibr7-0003319711409565">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Al Suwaidi</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Reddan</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes</article-title>. <source>Circulation</source>. <year>2002</year>;<volume>106</volume>(<issue>8</issue>):<fpage>974</fpage>–<lpage>980</lpage>.</citation>
</ref>
<ref id="bibr8-0003319711409565">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dumaine</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Collet</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Tanguy</surname>
<given-names>ML</given-names>
</name>
<etal/>
</person-group>. <article-title>Prognostic significance of renal insufficiency in patients presenting with acute coronary syndrome (the Prospective Multicenter SYCOMORE study</article-title>. <source>Am J Cardiol</source>. <year>2004</year>;<volume>94</volume>(<issue>12</issue>):<fpage>1543</fpage>–<lpage>1547</lpage>.</citation>
</ref>
<ref id="bibr9-0003319711409565">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herzog</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Littrell</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Arko</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Frederick</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Blaney</surname>
<given-names>M.</given-names>
</name>
</person-group> <article-title>Clinical characteristics of dialysis patients with acute myocardial infarction in the United States: a collaborative project of the United States renal data system and the national registry of myocardial infarction</article-title>. <source>Circulation</source>. <year>2007</year>;<volume>116</volume>(<issue>13</issue>):<fpage>1465</fpage>–<lpage>1472</lpage>.</citation>
</ref>
<ref id="bibr10-0003319711409565">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gibson</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Pinto</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>SA</given-names>
</name>
<etal/>
</person-group>. <article-title>Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality</article-title>. <source>J Am Coll Cardiol</source>. <year>2003</year>;<volume>42</volume>(<issue>9</issue>):<fpage>1535</fpage>–<lpage>1543</lpage>.</citation>
</ref>
<ref id="bibr11-0003319711409565">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Levey</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Stevens</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Schmid</surname>
<given-names>CH</given-names>
</name>
<etal/>
</person-group>. <article-title>A new equation to estimate glomerular filtration rate</article-title>. <source>Ann Intern Med</source>. <year>2009</year>;<volume>150</volume>(<issue>9</issue>):<fpage>604</fpage>–<lpage>612</lpage>.</citation>
</ref>
<ref id="bibr12-0003319711409565">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>AlHabib</surname>
<given-names>KF</given-names>
</name>
<name>
<surname>Hersi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>AlFaleh</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>The Saudi project for assessment of coronary events (SPACE) registry: design and results of a phase I pilot study</article-title>. <source>Can J Cardiol</source>. <year>2009</year>;<volume>25</volume>(<issue>7</issue>):<fpage>e255</fpage>–<lpage>e258</lpage>.</citation>
</ref>
<ref id="bibr13-0003319711409565">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cannon</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Battler</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Brindis</surname>
<given-names>RG</given-names>
</name>
<etal/>
</person-group>. <article-title>American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee)</article-title>. <source>J Am Coll Cardiol</source>. <year>2001</year>;<volume>38</volume>(<issue>7</issue>):<fpage>2114</fpage>–<lpage>2130</lpage>.</citation>
</ref>
<ref id="bibr14-0003319711409565">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stevens</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Schmid</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Greene</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations for estimating GFR levels above 60 mL/min/1.73 m2</article-title>. <source>Am J Kidney Dis</source>. <year>2010</year>;<volume>56</volume>(<issue>3</issue>):<fpage>486</fpage>–<lpage>495</lpage>.</citation>
</ref>
<ref id="bibr15-0003319711409565">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>El-Menyar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zubaid</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sulaiman</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>In-hospital major clinical outcomes in patients with chronic renal insufficiency presenting with acute coronary syndrome: data from a Registry of 8176 patients</article-title>. <source>Mayo Clin Proc</source>. <year>2010</year>;<volume>85</volume>(<issue>4</issue>):<fpage>332</fpage>–<lpage>340</lpage>.</citation>
</ref>
<ref id="bibr16-0003319711409565">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Navaneethan</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Pansini</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Perkovic</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Manno</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Pellegrini</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>DW.</given-names>
</name>
</person-group> <article-title>Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials</article-title>. <source>BMJ</source>. <year>2008</year>;<volume>336</volume>(<issue>7645</issue>):<fpage>645</fpage>–<lpage>651</lpage>.</citation>
</ref>
<ref id="bibr17-0003319711409565">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wong</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Goodman</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>RT</given-names>
</name>
<etal/>
</person-group>. <article-title>Temporal management patterns and outcomes of non-ST elevation acute coronary syndromes in patients with kidney dysfunction</article-title>. <source>Eur Heart J</source>. <year>2009</year>;<volume>30</volume>(<issue>5</issue>):<fpage>549</fpage>–<lpage>557</lpage>.</citation>
</ref>
<ref id="bibr18-0003319711409565">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wannamethee</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Shaper</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Perry</surname>
<given-names>IJ.</given-names>
</name>
</person-group> <article-title>Serum creatinine concentration and risk of cardiovascular disease: a possible marker for increased risk of stroke</article-title>. <source>Stroke</source>. <year>1997</year>;<volume>28</volume>(<issue>3</issue>):<fpage>557</fpage>–<lpage>563</lpage>.</citation>
</ref>
<ref id="bibr19-0003319711409565">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keltai</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tonelli</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mann</surname>
<given-names>JF</given-names>
</name>
<etal/>
</person-group>. <article-title>Renal function and outcomes in acute coronary syndrome:impact of clopidogril</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source>. <year>2007</year>;<volume>14</volume>(<issue>2</issue>):<fpage>312</fpage>–<lpage>318</lpage>.</citation>
</ref>
<ref id="bibr20-0003319711409565">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Melloni</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Peterson</surname>
<given-names>ED</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>AY</given-names>
</name>
<etal/>
</person-group>. <article-title>Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes</article-title>. <source>J Am Coll Cardiol</source>. <year>2008</year>;<volume>51</volume>(<issue>10</issue>):<fpage>991</fpage>–<lpage>996</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>